Breaking News
March 19, 2018 - AcelRx Announces Receipt of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA New Drug Application in Q2 2018
March 19, 2018 - Eye Docs Adopt EHRs Despite Reservations
March 19, 2018 - CRISPR enhances cancer immunotherapy
March 19, 2018 - Study finds first evidence of delayed aging among Americans
March 19, 2018 - Essential oils linked to abnormal breast development in boys
March 19, 2018 - ‘Tummy Tuck’ Relieved Postpartum Back Pain/Incontinence
March 19, 2018 - New biomarkers for neuroblastoma, a type of cancer in children
March 19, 2018 - Hookah Smoking Carries a Poisoning Risk
March 19, 2018 - Do Mood and Anxiety Affect MS Disability?
March 19, 2018 - Mean depth of ultrasonographic penetration greater in autism
March 19, 2018 - Platypus milk may help combat antibiotic resistance
March 19, 2018 - U.S. IDE study of THERMOCOOL SMARTTOUCH SF Catheter completes patient enrollment
March 18, 2018 - E-cigarette use exposes adolescents to potentially cancer-causing chemicals
March 18, 2018 - GOP Senator: Solve Opioid Crisis Through Community, Not Policy
March 18, 2018 - Why is ADHD more common in boys than girls?
March 18, 2018 - Measles alert after two passengers with the disease fly into US
March 18, 2018 - FDA looks to remove nicotine from cigarettes
March 18, 2018 - FDA moves to cut nicotine in cigarettes, helping smokers kick habit
March 18, 2018 - Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis
March 18, 2018 - Surgery Tied to Better Outcomes in Kids with T2D
March 18, 2018 - Scientists use nanotechnology to detect molecular biomarker for osteoarthritis
March 18, 2018 - Research establishes use of chimeric cells as potential therapy for Duchenne muscular dystrophy
March 18, 2018 - Researcher working to develop improved endoscopic probe for colonoscopies
March 18, 2018 - Researchers develop way to sequence entire fetal genome by modifying prenatal testing method
March 18, 2018 - FDA Approves PDUFA Fee Waiver for Gimoti New Drug Application
March 18, 2018 - P2Y12 Tx Subsidy Yields Positive Response from Docs, Patients
March 18, 2018 - Are Proteins in Formula Linked to Type 1 Diabetes?
March 18, 2018 - Exercise does not seem to increase bone marrow edema in healthy people
March 18, 2018 - Researchers delineate architecture of nuclear pore complex in yeast cells
March 18, 2018 - ‘It’s Just Ghetto-izing People’: What We Heard This Week
March 18, 2018 - Alzheimer’s disease: Neuronal loss very limited
March 18, 2018 - Study reveals impact of intense, changing work schedules experienced by medical interns
March 18, 2018 - Jobs That Keep the Mind Sharp … Even Into Retirement
March 18, 2018 - Facial Scarring Improved with Botulinum Toxin
March 18, 2018 - Data detectives shift suspicions in Alzheimer’s to inside villain
March 18, 2018 - Shorter Preventive TB Tx Effective for HIV+ Patients
March 18, 2018 - New technique for identifying alcoholism puts treatment options at patients’ and providers’ fingertips
March 18, 2018 - Researchers uncover four microRNAs as potential biomarkers for atrial fibrillation
March 18, 2018 - IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
March 18, 2018 - OncoBreak: Learning from Silence; ‘Rigged’ Drug System; NCCN Guidelines Questioned
March 18, 2018 - The coffee cannabis connection
March 18, 2018 - Novel centrifugal-flow pump for heart failure patients provides improved long-term outcomes
March 18, 2018 - U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
March 18, 2018 - Cath Lab Recap: iFR vs FFR $$; Ridaforolimus-Eluting Stent
March 18, 2018 - Tree care workers need better training to handle dangers on the job, study finds
March 18, 2018 - Dementia patients do not undergo diagnostic evaluation at onset of disease, study finds
March 18, 2018 - Transplanting enhanced interneurons restores brain rhythms in mouse model of Alzheimer’s
March 18, 2018 - Gene Therapy Flops for Critical Limb Ischemia
March 17, 2018 - Study spotlights risks in anesthesiologist handoffs
March 17, 2018 - Verb fluency test may be useful tool for differential diagnosis of cognitive failure
March 17, 2018 - Health Tip: Suggestions to Improve Your Cholesterol
March 17, 2018 - Fructans Suspect in Non-Celiac Gluten Sensitivity
March 17, 2018 - Aspirin therapy appears safe before thyroid surgery
March 17, 2018 - Minimally invasive surgical device may one day provide lasting heart repair
March 17, 2018 - UIH and RaySearch enter into new partnership
March 17, 2018 - Is BMI Too Inexact? | Medpage Today
March 17, 2018 - Sleep apnea study finds male-female differences in cerebral cortex thickness, symptoms
March 17, 2018 - Leicester research could help identify people with asthma of different severities
March 17, 2018 - Biosense Webster enrolls and treats first AF patient in clinical study of new RF balloon catheter
March 17, 2018 - Participants in rogue herpes vaccine research take legal action
March 17, 2018 - Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease
March 17, 2018 - AAP: Prevent Medication Errors by Improving Processes
March 17, 2018 - Severe sleep apnea during REM sleep tied to acute CV events
March 17, 2018 - Alzheimer’s disease also affects small blood vessels
March 17, 2018 - Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 17, 2018 - Switching Biologics in Psoriasis Care
March 17, 2018 - Polygenic risk score may identify alzheimer’s risk in younger populations
March 17, 2018 - Genetic heart mutations account for fewer sudden and unexplained infant deaths
March 17, 2018 - Clinical trial to test efficacy of stem cell transplants in stopping ALS muscle deterioration
March 17, 2018 - Researchers team up to improve life for children with microcephaly
March 17, 2018 - Health guide for young women regarding labiaplasty
March 17, 2018 - Inhaled Nitrite Flops as HFpEF Therapy
March 17, 2018 - California mental health tax providing services to needy in L.A. County, study finds
March 17, 2018 - Cancer survivors become fatigued more quickly than their peers, study finds
March 17, 2018 - Study finds common presence of nightmares among U.S. military personnel
March 17, 2018 - Yellow fever outbreak in Brazil necessitates vaccination for travelers
March 17, 2018 - Health Tip: Waist Size May Help Predict Heart Attack
March 17, 2018 - Low-Dose Combo Pill Successfully Takes Down High BP
March 17, 2018 - Most children with sickle cell anemia not receiving key medication to stay healthy
March 17, 2018 - YCC launches new Yale Center for Immuno-Oncology
Light-activated cancer drugs without toxic side effects are closer to becoming reality

Light-activated cancer drugs without toxic side effects are closer to becoming reality

image_pdfDownload PDFimage_print

Future cancer drugs that are activated by light and don’t cause the toxic side-effects of current chemotherapy treatments are closer to becoming a reality, thanks to new research made possible by the Monash Warwick Alliance, an intercontinental collaboration between the University of Warwick (UK) and Monash University (Australia).

Led by Robbin Vernooij, a joint PhD student from the Monash Warwick Alliance, fresh insight has been gained into how a pioneering platinum-based chemotherapy drug candidate – trans,trans,trans-[Pt(N3)2(OH)2(py)2] – functions when activated by light.

The treatment – originally developed by Professor Peter Sadler’s research group in the University of Warwick’s Department of Chemistry – is an inorganic-metal compound with an unusual mechanism, which kills cancer cells in specific targeted areas, in an effort to minimize toxic side-effects on healthy tissue.

Completely inactive and non-toxic in the dark, the treatment can be inserted into cancerous areas, its functions triggered only when directed light hits it – causing the compound to degrade into active platinum and releasing ligand molecules to attack cancer cells.

Using an old spectroscopic technique – infrared spectroscopy – the researchers observed what happens to the structure of the compound by following the metal as well as molecules released from the compound.

The researchers shone infrared light on the inorganic-metal compound in the laboratory, and measured the vibrations of its molecules as it was activated.

From this, they discovered the chemical and physical properties of the compound: some of the organic ligands, which are attached to the metal atoms of the compound, become detached and are replaced with water whilst other ligands remain stable around the metal.

This fresh insight into the mechanics of the treatment offers new hope that photoactive chemotherapy drug candidates, such as trans, trans,trans-[Pt(N3)2(OH)2(py)2], will progress from the laboratory to future clinical trials.

Robbin Vernooij, lead author and joint researcher from the Monash Warwick Alliance, commented:

‘”The current shortcomings of most chemotherapeutic agents are unfortunately undeniable, and therefore there is ongoing effort to develop new therapies and improve our understanding of how these agents work in effort to develop not only more effective, but also more selective, therapies to reduce the burden on patients.

”This is an exciting step forward, demonstrating the power of vibrational spectroscopic techniques combined with modern computing to provide new insights on how this particular photoactive chemotherapeutic agent works, which brings us one step closer to our goal of making more selective and effective cancer treatments”

Peter Sadler, Professor of Chemistry at the University of Warwick, commented:

“About half of all chemotherapy treatments for cancer current use a platinum compound, but if we can introduce new platinum compounds that avoid side-effects and are active against resistant cancers, that would be a major advance.

“Photoactivated platinum compounds offer such possibilities. They do not kill cells until irradiated with light, and the light can be directed to the tumor so avoiding unwanted damage to normal tissue.

“It is important that we understand how these new light-activated platinum compounds kill cancer cells. We believe they attack cancer cells in totally new ways and can combat resistance. Understanding at the molecular levels requires use of all the advanced technology that we can muster. In this case, advances have been made possible by a highly talented research student working with state-of-the-art equipment on opposite sides of the globe.

“We hope that new approaches involving the combination of light and chemotherapy can play a role in combatting the current shortcomings of cancer therapy and help to save lives.”

The majority of cancer patients who undergo chemotherapy treatment currently receive a platinum-based compound, such as cisplatin. These therapies were developed over half a century ago, and cause toxic side-effects in patients, attacking healthy cells as well as cancerous ones.

There is also a growing resistance to more traditional cancer therapies, so new treatments are desperately required.


Tagged with:

About author

Related Articles